Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion Journal Article uri icon
  • Insulin-like growth factor-I (IGF-I) has been proposed as a treatment for stroke. However, it does not efficiently cross the blood-brain barrier (BBB). Intracerebroventricular injection of IGF-I has been shown to offer protection against cerebral ischemic damage in rats although this invasive method of administration may not be practical in humans. Non-invasive intranasal (IN) delivery of IGF-I to the brain is a promising alternative. We have assessed the therapeutic effect of IN IGF-I in rats following middle cerebral artery occlusion (MCAO). Treatment was initiated 10 min after the onset of MCAO and then again 24 and 48 h later. Intranasal dosing of 75 microg IGF-1 (225 microg total IGF-I over 48 h) significantly reduced corrected infarct volumes by 60% vs. control (P<0.01) and hemispheric swelling by 45.6% vs. control (P<0.05). Neurologic function, assessed by the postural reflex, flexor response and adhesive tape tests, was also improved by IN IGF-I as compared to control. Our study indicates IN delivery of IGF-1 holds significant promise as a non-invasive and efficacious method of bypassing the BBB for the treatment of stroke.

  • Link to Article
    publication date
  • 2001
  • published in
  • *Administration, Intranasal
  • Animals
  • Brain Edema/drug therapy/etiology/prevention & control
  • Brain Ischemia/*drug therapy/pathology/physiopathology
  • Brain/*drug effects/pathology/physiopathology
  • Disease Models, Animal
  • Drug Administration Schedule
  • Infarction, Middle Cerebral Artery/*drug therapy/pathology/physiopathology
  • Insulin-Like Growth Factor I/*pharmacology
  • Movement Disorders/drug therapy/etiology/physiopathology
  • Neuroprotective Agents/pharmacology
  • Olfactory Mucosa/cytology/drug effects/metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Recovery of Function/*drug effects/physiology
  • Additional Document Info
  • 308
  • issue
  • 2